Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joshua A Ray

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Journal of Market Access & Health Policy|April 29, 2016
The value of innovation under value-based pricingSantiago G Moreno, Joshua A Ray
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 15, 2010
An evaluation of the cost-effectiveness of rituximab in combination with chemotherapy for the first-line treatment of follicular non-Hodgkin's lymphoma in the UKJoshua A Ray, Emma Carr, Gavin Lewis, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|October 8, 2009
Cost-effectiveness studies of diabetes prevention in high-risk patientsAndrew J Palmer, William J Valentine, Joshua A Ray
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|January 24, 2007
Health economic implications of irbesartan treatment versus standard blood pressure control in patients with type 2 diabetes, hypertension and renal disease: a Hungarian analysisAndrew J Palmer, William J Valentine, Joshua A Ray, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 22, 2016
Cost-Effectiveness Model for Chemoimmunotherapy Options in Patients with Previously Untreated Chronic Lymphocytic Leukemia Unsuitable for Full-Dose Fludarabine-Based TherapyUrsula Becker, Andrew H Briggs, Santiago G Moreno, et al.
Current Medical Research and Opinion|April 1, 2006
Counting the costs of overweight and obesity: modeling clinical and cost outcomesDaniel M D Tucker, Andrew J Palmer, William J Valentine, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 23, 2008
Cost-effectiveness of early versus late cinacalcet treatment in addition to standard care for secondary renal hyperparathyroidism in the USAJoshua A Ray, Rohit Borker, Beth Barber, et al.
Clinicoeconomics and Outcomes Research : CEOR|February 21, 2012
Cross-market cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small cell lung cancerAlain Vergnenègre, Joshua A Ray, Christos Chouaid, et al.
Current Medical Research and Opinion|April 5, 2007
An economic assessment of analogue basal-bolus insulin versus human basal-bolus insulin in subjects with type 1 diabetes in the UKAndrew J Palmer, William J Valentine, Joshua A Ray, et al.
Current Medical Research and Opinion|October 22, 2005
Review of the cost of diabetes complications in Australia, Canada, France, Germany, Italy and SpainJoshua A Ray, William J Valentine, Kristina Secnik, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Journal of Market Access & Health Policy|April 29, 2016
The value of innovation under value-based pricingSantiago G Moreno, Joshua A Ray
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 15, 2010
An evaluation of the cost-effectiveness of rituximab in combination with chemotherapy for the first-line treatment of follicular non-Hodgkin's lymphoma in the UKJoshua A Ray, Emma Carr, Gavin Lewis, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|October 8, 2009
Cost-effectiveness studies of diabetes prevention in high-risk patientsAndrew J Palmer, William J Valentine, Joshua A Ray
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|January 24, 2007
Health economic implications of irbesartan treatment versus standard blood pressure control in patients with type 2 diabetes, hypertension and renal disease: a Hungarian analysisAndrew J Palmer, William J Valentine, Joshua A Ray, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 22, 2016
Cost-Effectiveness Model for Chemoimmunotherapy Options in Patients with Previously Untreated Chronic Lymphocytic Leukemia Unsuitable for Full-Dose Fludarabine-Based TherapyUrsula Becker, Andrew H Briggs, Santiago G Moreno, et al.
Current Medical Research and Opinion|April 1, 2006
Counting the costs of overweight and obesity: modeling clinical and cost outcomesDaniel M D Tucker, Andrew J Palmer, William J Valentine, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 23, 2008
Cost-effectiveness of early versus late cinacalcet treatment in addition to standard care for secondary renal hyperparathyroidism in the USAJoshua A Ray, Rohit Borker, Beth Barber, et al.
Clinicoeconomics and Outcomes Research : CEOR|February 21, 2012
Cross-market cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small cell lung cancerAlain Vergnenègre, Joshua A Ray, Christos Chouaid, et al.
Current Medical Research and Opinion|April 5, 2007
An economic assessment of analogue basal-bolus insulin versus human basal-bolus insulin in subjects with type 1 diabetes in the UKAndrew J Palmer, William J Valentine, Joshua A Ray, et al.
Current Medical Research and Opinion|October 22, 2005
Review of the cost of diabetes complications in Australia, Canada, France, Germany, Italy and SpainJoshua A Ray, William J Valentine, Kristina Secnik, et al.
Pageof 2